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An ECG every 3 years is enough to follow patients with myotonic dys-
trophy
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Patients (pts) with type I myotonic dystrophy (MD) were reported as at
high risk of arrhythmias, mainly conduction disturbances. The purpose of the
study was to evaluate the mean time of change of noninvasive investigations
and to propose recommendations for the follow-up of patients with MD. 
Methods: 129 asymptomatic pts, mean age 41±14 years, with MDl, were
consecutively recruited. ECG, left ventricular ejection fraction (EF) determina-
tion, Holter monitoring, were obtained and repeated each year in pts without
conduction abnormalities. Electrophysiological study (EPS) was performed in
51 pts. Follow-up duration ranged from 1 to 23 years, with a mean duration of
10 ± 5 years. 
Results: At initial study, ECG and Holter monitoring were normal in 72
and 89 pts; EF was normal in all but 6 pts (60±10.5 %). At the last study, the
ECG did not change in 65 % of pts; in 49 pts with normal ECG, the ECG
remained normal in 32 pts; first degree (d) AV block (B) developed in 11 pts,
left hemiblock (HB) in 3 pts, complete bundle branch block (BBB) in 3 pts; 3
pts with a BBB developed another localization of conduction disturbance. HV
increase was noted in patients with first d AVB and HB or BBB, and never in
pts with normal ECG. Initially normal Holter monitoring (n=61) remained
normal in 44 pts (72 %); sinus pauses were noted in 6 pts and non sustained
ventricular tachycardia in one pt. In 19 pts with initial abnormalities, Holter
monitoring became normal in 10 of them. LVEF did not change significantly
(61±11 at first study, 58±11 % at 2nd study). The ECG modifications deve-
loped after a mean follow-up of 5 ±1 years. The shorter time of the occurrence
of a significant modification was 4 years. However, to be sure to detect a
significant change and risk of arrhythmias, a period of 3 years (5± 2 standard
deviations) could be retained.
Conclusions: HV increase was noted only in patients with abnormal ECG.
No change of ECG was noted in patients with normal ECG before 4 years.
The repetition of ECG every 3 years is recommended and EPS should be indi-
cated when ECG became abnormal.
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Does the physical examination still have a role in patients with poten-
tial chronic heart failure?
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Objective: Define the prognosis value of the congestive clinical signs of
heart failure (CHF) in an out-patient clinic compared to other clinical variables.
Background: Clinical examination is non-specific to diagnose CHF.
However the prognosis value of the clinic signs of CHF is unknow.
Methods: Analysis of referrals to a community clinic of suspected chronic
heart failure with a clinical examination. Clinical signs of CHF were defined
as no sign, fluid retention (FR; oedema, ascitis, hepatomegaly, jugular vein
distension), lung crackles (LC) and their combination (FR+LC). Systolic heart
failure was defined as LVEF<45% (S-HF), CHF with normal ejection fraction
was defined as LVEF ≥45% and NT-proBNP>50pmol.l-1 (HeFNEF), others
were defined as No-HF. 
Results: Of 1881 patients referred, 853 patients had S-HF, 321 had HeFNEF
and 707 No-HF. Their median (IQR) age was 72yrs (64-78), LVEF was 47%
(35-59) and 40% were women. 1207 patients had no clinical signs of CHF of
whom 41% were SHF and 16% HeFNEF, 85 had LC of whom 43% were S-HF
and 20% HeFNEF, 417 had FR of whom 49% had S-HF and 21% HeFNEF and
172 had LC+Frof whom 43% had S-HF and 16% HeFNEF. Patients with
LC+RF were more breathless, had more frequently an ischaemic heart disease
and had a lower ejection fraction and a lower right ventricle function measured
by the tricupsid annular plane systolic excursion. During a median (IQR) follow
up of 64 (44-76) months, mortality was 40%. In multivariable analysis,
increasing age, NYHA class, heart rate, LC+FR, FR, ischaemic heart disease and
chronic obstructive pulmonary disease predicted an adverse prognosis;
increasing diastolic blood pressure and female sex predicted a better outcome.
Using Kaplan Meier curves, LC and FR indicated a similar bad prognosis,
LC+FR indicated the worse prognosis when all the patients were considered (log
Rank=185, p<0.0001), or the three HF groups separately.
Conclusion: Clinical signs of CHF are powerful predictors of prognosis in
outpatient clinic. Presence of fluid retention and lung crackles showing the
worse prognosis. These clinical signs should be assessed systematically to eva-
luate the prognosis in symptomatic patients.
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Patterns of acute heart failure in nonagenarians
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Background: Since heart failure (HF) often occurs in subjects >70y old
and the population of Western countries is getting older, the incidence of HF
is expected to dramatically increase in the future. However, limited informa-
tion is available on HF in the extreme elderly. 
Methods: We retrospectively studied patients >90y old patients admitted to
our hospital for acute HF between 2007 and March 2010. Patients with incomplete
clinical records were excluded. Main foci were : epidemiological data, initial pre-
sentation, results of routine biological and imaging tests and clinical outcome.
Results: 56 patients (mean age 94 [range 91-97], 60% female) were
included. Cardiovascular risk factors were hypertension (75%), hypercholeste-
rolemia (16%) and diabetes (7%). 56% of patients had no underlying cardio-
myopathy while 16% had coronary artery disease, 13% had valve disease, 5%
had hypertension and 10% had cardiomyopathy due to multiple factors. On
presentation, mean creatinine was 163 mmol/L [79-317], hemoglobin was 11,5
g/dL [9,9-12,4], and BNP was 2617 pg/mL [128-14.574]. Mean ejection frac-
tion was 46% [34-58]. The 3 main precipitating factors of acute HF were
hypertension (23%), infection (23%) and acute coronary syndrome (20%). In
15% of patients, no reason for acute decompensation could be identified. More
than 50% of patients were admitted to the ICU, 30% required breathing assis-
tance and 5% required inotropic drugs. Average hospital stay was 6 days [2.9-
9.5]. 63% of patients were discharged home; hospital mortality was 20%.
Medical treatment at discharge included diuretics (90%), ACE inhibitors
(60%) and beta-blockers (45%). 
Conclusion: Acute HF in nonagenarians is associated with poor prognosis.
Main characteristics are a preserved ejection fraction, no obvious underlying
cardiomyopathy and infection and hypertension as precipitating factors.
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Introduction: A heart failure with preserved ejection fraction ( HFPEF) is
present in half the patients with heart failure (HF); the prognosis in more
recent studies has been shown to be essentially similar to that of systolic HF.
The objective of our study is to define the clinical, biological and echocardio-
graphic predictors of outcome in patients with HFPEF. 
Material and methods: We included 1200 patients, admitted in Ibn Rochd
Center of Cardiology from May 2006 to February 2010. HFPEF was defined
as LVEF ≥ 45% and receiving a loop diuretic for breathlessness. All patients
were evaluated clinically with monitoring of blood pressure (BP), 6 min walk
test and electrocardiogram. Two-dimensional echocardiography and laboratory
tests were performed in all patients.
Results: Of 1200 patients, 63 ( 5.25%) had HFPEF; the median age was 66
years ( 42- 94) and 61.9% were men. 49.2% of the patients were hypertensive
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and 33% were diabetic, and 61.9% were in NYHA class II, and 23.8% were
in NYHA class III. The median of 6min walk test was 118m. The mean LVEF
was 46% (40- 69). Hypertensive (44.4%) and Ischemic heart disease (17.46%)
remain the two most frequent etiology. During a median follow up of 32
months, mortality was 16%. By univariable analysis, NHYA class; 6min walk
distance; atrial fibrillation; right ventricular dysfunction and systolic pulmo-
nary artery pressure (sPAP) were associated with an adverse prognosis.
In multivariable analysis, increasing age, NYHA class, and renal failure were
predictors of adverse prognosis; beta-blockers treatment, increasing Hb and
female sex were predictors of a better outcome.
Conclusion: As several studies, clinical and biological variables were more
powerful predictors of outcome in HFPEF than echocardiographic variables
which are recommended to identify diastolic function.
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Background: Breast Cancer (BC) is the most frequent cancer, whereas CV
diseases such as myocardial infarction (MI) are the leading cause of death. BC
and MI share common major risk factors such as obesity. We aimed to analyse
the characteristics of women with a history of BC in the setting of acute MI.
Patients and methods: Among the 2087 consecutive women included
between 01/01/2001and 31/12/2009 in the French regional RICO survey data-
base, 73 (3%) had a history of BC. Each woman with prior BC (n=73) was
matched, with respect to age, with 5 women without prior BC (n=365). 
Results: Women with prior BC were 74 (65-80) year old. Time from BC
diagnosis to acute MI was 10 (3-16) years. Most BC had been treated by sur-
gery and/or radiation therapy, and 37% had also received hormone therapy.
CV risk factors (smoking, obesity), type of MI, acute management and in-hos-
pital complications were similar for the 2 groups. Chronic statin use and
admission blood lipids were also identical for the 2 groups. However, median
admission CRP levels were lower in women with a history of BC (1.0(1.0–9.8)
vs. 5.6 (2.8–13.6) mg/l, respectively, p<0.001). Strikingly, peak CK and tro-
ponin Ic levels, the latter of which reflects infarct size, were dramatically
lower, by 40%, and 26 %, respectively, in the BC group (310 (136–777) vs.
501 (198-1324) UI/l, p=0.022 and 9.20 (3.33-19.55) vs. 12.36 (2.77-41.00) µg/
l, p=0.166 respectively). By linear regression analysis, prior BC remains an
independent predictor of reduced peak CK (B(SE)=-626.8(260), p=0.017),
even when adjusted for potential confounders (anterior wall location, STEMI,
multivessel disease, time to admission).
Conclusions: In women currently admitted for acute MI, a non-negligible
proportion had prior BC. Women with prior BC had a similar risk profile and
lipid levels to those in women without prior BC. However, they were charac-
terized by a lower level of inflammation and smaller infarct size than their
counterparts without BC. Further investigations are ongoing to determine
whether hormone therapy such as oestrogen receptor modulators could account
for the observed effects in this population. 
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Pharmacological treatment of chronic heart failure in the region of
Marrakech : where are we compared to the recommendations?
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Introduction: heart failure (HF) is a frequent pathology which profited
from important therapeutic progress. The respect of the international recom-
mendations is essential in order to optimize its managment.
The objective of this study was to evaluate the adequacy of our prac-
tice with the international recommendations concerning the pharmacologic
management of chronic HF.
Patients and methods: It is about an observational prospective study over
six months including of the patients followed in cardiologic consultation for
chronic HF. The data collected the demographic elements(old, sex…) elements
concerning HF (class NYHA, etiology, number of decompensation during the
previous year…) and data concerning the pharmacological treatment pres-
cribed (molecules, doses, tolerance of the treatment, the control of the side
effects by the electric and biological complementary examinations.). The ade-
quacy of this treatment compared to the French recommendations of 2007 was
evaluated by a cardiologist senior who was not responsible for the follow-up
of the patient.
Results: Hundred two patients were included (42 women and 60 men with
a sex ratio of 1.15). The Middle Age was of 56.9 +-26.1 years. All the patients
(100%) were treated by the diuretic,78% of the cases were under converting
enzyme inhibitors (ACE),85% of the patients were under bétabloquants (BB),
75% of the patients were put under the triad diuretic- ACE- BB. The digitali-
ques had been prescribed at 21,4% of the patients who presented a chronic car-
diac failure in arrhythmia. The recommended target doses was noted in 35,7%
for ACE inhibitors, 25% for BB and 14,3 for diuretics.
Conclusion: Our study reveals an insufficient adequacy of our practice
with the international recommendations. Improving the management of Hf
based on the knowledge of the various therapeutic classes recommended in
the HF and their target doses.The creation of a unit of HF seems essential
then.
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The diagnosis of cardiac sarcoidosis (CS) (56 female-74 male; 73 White-
36 Black; age at CS: 40.5 ± 11.7 years) was defined by clinical signs (20%)
and/or evidence of at least two procedures abnormalities: ECG (64%), echo-
cardiography (71%), Magnetic Resonance Imaging (MRI) (58%) and myocar-
dial scintigraphy (72%). With a 54 month-median follow-up, 124 patients
were evaluable. The first line therapy was steroids alone in 57% of cases, ste-
roids with immunosuppressive (IS) drug in 43%. A relapse of the CS was
noted in 35 patients, a median time of 27 months. 
The RR of relapsing at any time was 3.1 times higher in Black
(P=0.008) and 4 times more when baseline abnormal myocardial MRI
(P=0.008). A recovery was achieved by 91 patients (73%), a stabilisation in
23% and 3% worsened. The relative risk (RR) of not recovering at any time
was 5.4 times higher in patients who had a steroids treatment duration of
less than 24 months (P < 0.0001), 2.4 times higher in patients with a ner-
vous system involvement (P = 0.018) and 3.7 times higher in those who
received a first line therapy with weekly methotrexate (P = 0.009). It was
21 times lower in patients who received monthly bolus of cyclophospha-
mide (CY) (P=0.004). 
Death occurred in 13 patients (10%), related to CS in two patients. The 5-
year survival rate was 91%. CS had a good prognosis under steroids alone or
associated with an IS drug with a global recovery rate of 73% and a 5-year
Survival rate of 91%. The risk of not recovering was associated with a steroids
treatment duration of less than 24 months, and the use of a methotrexate first
line therapy whereas CY was associated with a better prognosis. The identified
independent risk-factors for relapsing were Black origin and a baseline
abnormal cardiac MRI. This cohort demonstrates the need of maintaining a
careful clinical and paraclinical follow-up of patients with a cardiac sarcoi-
dosis with a more than 24-month steroids therapy.
